Fig. 5: MPI 8 exhibits antithrombotic properties in mice.

A–D MPI 8 reduced fibrin clot formation and platelet accumulation in mouse cremaster arteriole thrombosis model. A Schematic representation of the thrombosis model: Platelets and fibrin are tagged with fluorescent antibodies and can be visualized as they accumulate at the site of injury upon laser-induced injury. B Median fluorescence intensity representative of fibrin accumulation over time. C Median fluorescence intensity representative of platelet accumulation over time. D Representative images of thrombus growth at 0–3 mins in mice which were treated with saline or MPI 8. All results shown are mean +/− SD of n = 3 mice. E–G MPI 8 delays time to occlusion in carotid artery thrombosis model. E Schematic representation of the thrombosis model. Artery patency was monitored by Doppler flow probe. Injury was induced by topical application of FeCl₃ and patency is plotted versus time, comparing the saline control and MPI 8. UHRA-10 was used as a control. F At 100 mg/kg, MPI 8 is more effective at delaying time to occlusion. A log rank analysis test shows that the curve of MPI 8 is significantly different from the curve of UHRA-10 (MPI 8 vs UHRA-10 ***P < 0.0005). G At 200 mg/kg, MPI 8 and UHRA-10 have reached a similar level of patency, likely a maximum in this model using these inhibitors. All results shown are mean +/− SD of n = 8 mice. A log rank analysis test indicates the two curves of MPI 8 compared to the saline control are significantly different (**P < 0.005). H, I MPI 8 treatment inhibits thrombus formation in inferior vena cava thrombosis model. H a representation of the mouse model. I Thrombus weights of untreated (vehicle control) and treated (MPI 8) mice. After removal of 2 outliers, due to a lack of clot formation, data were statistically significantly different at p = 0.0003 in an unpaired, two-tailed T-test with Welch’s correction. Results shown are mean of n = 8 mice. Figure 5A, E, H were created using BioRender.com.